



CURRICULUM VITAE

Prof. BARONE MICHELE

Specialist in Gastroenterology
Ph.D. Gastroenterological Sciences

Birthdate	June 25, 1960
Birthplace	Bari, Italy
Family status	married with two children
Home address	Viale L. De Laurentis 23/D, Bari 70124 Bari, Italia
Business address	Gastroenterology Unit University "Aldo Moro" of Bari Ospedale Policlinico, Piazza G. Cesare 11 70124 Bari, Italy
e.mail	michele.barone@uniba.it
ORCID ID	orcid.org/0000-0001-8284-5127

EDUCATION

College	Liceo Scientifico "E. Fermi" Bari 1974-1979: Bachelor in general Science
Medical School	School of Medicine, Univ. di Bari, 1979-1985; Doctor in Medicine <i>cum laude</i> on November 11, 1985
License to practice Medicine	December 16, 1985
Specialization	Specialist in Gastroenterology on July 28, 1989 University of Bari

APPOINTMENTS AND POSITIONS

Membership of Italian Medical Ass.	Bari, February 25, 1986
Research Associate	Dept. of Surgery, Univ. of Pittsburgh, PA, USA from Jan 1986 through April 1990
Assistant Physician	Dept of Surgery, Univ. of Pittsburgh, PA, USA from Jan 1986 through April 1990
Philosophy Doctor	Gastroenterological Sciences, 13/10/1995
Emergency Dept. Assistant	from April/1/1993 to April/1/1995
Family Doctor	from August 0, 1994 to March 31, 1995
Teaching activities:	1993-94 - "Biochemistry" and "Nutrition"- 1994-95 - "Digestive disease". Nursing School
Medical Doctor as Specialist in Gastroenterology	in the Dept. of Gastroenterology from October 1995 to October 2006
Medical doctor and Research associate	from November 1, 2006, to March 2013, Gastroenterology Unit, University of Bari
Chief of Gastroenterology Unit	from April 2013 to October 2014, University of Foggia
Medical doctor and Research associate	from November 1, 2014 until now, Gastroenterology Unit, University of Bari
Teaching activities	Prof. of Gastroenterology, Faculty of Medicine, University of Bari.

HONORS AND AWARDS

Scholarship provided by the University of Bari for experimental studies on liver cell cultures.

Award for presentation of the best poster. National Congress on the Digestive Disease, Milan, Novembre 14-18, 1998.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS AND SOCIETIES

Member of Italian Association for the Study of Liver Disease since 1987

Member of Italian Association of Gastroenterology since 1994

Member of the Italian Association for Prenteral and Enteral Nutrition since 2011

Member of Europeant Association for the Study of Liver since 2012

RESEARCH ACTIVITY

The scientific interest during the first years of reasearch has been focused on the study of factors that modulate hepatic proliferative processes (hormones, growth factors, immunofilline, bile salts, proteins modulating cell cycle, etc..) using various experimental models in vivo and in vitro. The results achieved, working at first at the University of Pittsburgh as a Research Associate, and then at the University of Bari, allowed both the purification and characterization of HSS (Hepatic stimulatory Substance), later named ALR (Augmenter of Liver Regeneration), and the definition of the role of bile salts in the modulation of proliferation, both in the liver and in the colon. Later on, the collaboration with the “CEINGE Advanced Biotechnology” of Naples, allowed to explore the role of bile salts as promoting agents in cancer of the liver and colon, indicating the involvement of protein kinases in the proliferative signal induced by bile salts.

In the last decade, the scientific activity has been focused on liver and colorectal cancer. Several studies have been performed on the influence of sex steroid hormones on the development of these tumors. In addition, the therapy and ethiopatogenesis of hepatocellular carcinoma have been widely studied. Moreover, studies on the policies of organ allocation for liver transplantation have led to the publication of several scientific papers in this field of research. More recently, several publications on the role HBV and HCV in liver disease and in the field of nutrition, including artificial nutrition, have been have published.

The research on colon carcinogenesis has led to the development of an Italian patent n. BA2008A000008 on behalf of LEO ALFREDO and BARONE MICHELE entitled "Compositions comprising phytoestrogens selective for estrogen receptor beta and dietary fibers"

PARTICIPATION TO NATIONAL OR INTERATIONAL MEETINGS

1. Participation as speaker, to the Advanced Course in Gastroenterology on Etiopathogenesis of colon cancer on the theme "Growth Factors". November 1992
2. Participation as speaker, to the conference Aspects of Oncology in liver disease, with the oral presentation entitled "In vitro study on the ability of bile salts to modulate the proliferation of rat hepatocytes." November 1993.
3. Participation as speaker, to the National Conference of the Society of Gastroenterology, with the oral presentation, entitled " Mitogenic effects of bile salts on the proliferative activity of rat liver." 1993.
4. Participation as speaker, to the National Conference of the Society of Gastroenterology, with the oral presentation, entitled "Effects of bile salts on the regenerative response of rat liver induced by partial hepatectomy." 1994.
5. Participation as speaker, to a workshops in Hepatogastroenterology, with the oral presentation, entitled "The Role of bile salts in liver damage and repair." June 26-30, 1996,
6. Participation as speaker, to the National Conference of the Society of Gastroenterology, with the oral presentation, entitled "Mitogenic effects of bile salts on the liver." November 23-28, 1996.
7. Participation as speaker, to the congress "New Frontiers in the treatment of Liver Disease", on "Bile salts and cell proliferation of colonic mucosa: implication in colon carcinogenesis." December 5-6, 1997.
8. Participation to the National Conference of the Society of Gastroenterology, poster presentation entitled "Involvement of bile salts in the modulation of cell proliferation of the bile ducts." The report was awarded with the prize for the best scientific contribution. November 14-18, 1998.
9. Participation as speaker, to the National Conference of the Society of Gastroenterology, with the oral presentation entitled "Expression of cyclin kinase inhibitor protein-dependent (CDKI) in rat hepatocytes during quiescence or proliferation." November 18-22, 2000.
10. Participation as invited speaker, to the International Conference "Estrogens 2001", on the topic "The Role of estrogens in hepatocyte proliferation." Modena, May 21-22, 2001.

11. Participation as speaker, to the National Conference of the Society of Gastroenterology, with the oral presentations entitled "Influence of UDC-enriched diet on tumor growth in transgenic mice that overexpress the HBV X protein" and "Demonstration of direct stimulatory effect of bile salts on epithelial cell proliferation in rat colon." December 1-5, 2001.
12. Participation as invited speaker, to the Training Course "Interregional continuous update in gastroenterology and digestive endoscopy in adults and children", Bari 27/10/2003.
13. Participation as invited speaker, to the conference "New frontiers in surgical oncology", on the topic "Ultrasound contrast medium in the diagnosis of liver tumors." Bari, November 11-12, 2004.
14. Participation as invited speaker, to the training course on "Psycho-Oncology: neuropsychological bases, clinical features, mode of action", Bari 9/12-16/26 May 2005, on the topic "Oncology in Gastroenterology."
15. Participation as invited speaker, to the training course for "Emergencies in Gastroenterology: how to recognize them, the first approach, the management after the acute phase", on the theme "Biliary sepsis." Bari, October 20, 2006.
16. Coordinator of the multicenter, phase III, Pec 03302 sponsored by Schering-Plough entitled: Evaluation of PEG-IFN α -2b administration on HCC recurrence in cirrhotic patients treated by Already ocoregional or surgical therapy ", duly approved by the Ethics Committee of the Ospedale Policlinico, Bari.
17. Participation as moderator and speaker to the Training Course "Evaluation and management of chest pain", Bari, November 17, 2007.
18. Participation as moderator and speaker to the Training Course "EMPATIE", on the topic "Management of the patient with chronic HBV in clinical practice." Monopoli, May 2009.
19. Participation as invited speaker to the Training Course "Viral hepatitis and chronic complications," on the topic "The management of patients with chronic HBV infection in clinical practice." Massafra, June 6, 2009.
20. Participation as invited speaker to the Third Trisocietario Pugliese Congress on "Tumors of the upper digestive tract," on the topic "Therapeutic management of patients with HBV positive in the course of lymphoma." Bari, June 11-13, 2009,
21. Participation as invited speaker in the XIII National Congress USASI, on the topic "Tumors of the biliary tract and pancreas". Bari, November 20, 2009.

22. Participation as invited speaker to "Seminars in pathophysiology and clinical surgery - Year XIX -" on the topic "Gastroenterological complications after bariatric surgery." Bari, November 26-27, 2009,
23. Participation as moderator and speaker to the Training Course "EMPATIE", on the topic "Management of the patient with chronic HBV in clinical practice." Bari, December 5, 2009,
24. Participation as invited speaker to the conference " HCV infection: from diagnosis to therapy," on the theme "Re-treatment and patients difficult to treat". Bari, December 19, 2009,
25. Participation as invited speaker to the conference "Hepatology: ... not only virus," on the topic "Tenofovir". Bari, January 22-23, 2010,
26. Participation to the "43rd Annual General Meeting AISF", Rome, 25-26 February 2010.
27. Participation to "EPA-NET Congress; Italian network for the treatment of chronic hepatitis B", Sorrento, February 16-17, 2010.
28. Participation as invited speaker in the conference "Monothematic Days. Viral hepatitis: an open question" on the topic "Clinical case not solved". Bari, March 2, 2010,
29. Participation as lecturer to the conference "EPA-NET", the Italian Network for the treatment of chronic hepatitis B. on the topic "Thread clinical cases and decision-making processes." Bari, June 4, 2010,
30. Participation as invited speaker to the conference "The Artificial Nutrition Home Care in Puglia after 25 years: Risks, Issues and New Perspectives" on the theme "Experience with outpatient." Trani, June 12, 2010,
31. Participation as invited speaker to the CME course "Food and Health", on the topic "Artificial Nutrition Homecare". Bari 03/12/2010
32. Participation as speaker to the National Conference FISMAD, with the oral presentation entitled "Role of bone marrow stem cells in a model of intestinal carcinogenesis: $Apc^{Min/+}$ transgenic mice." March 5-8, 2011,
33. Participation to the GAVeCeLT course "Role of PICC into the line in cancer patients", Milan March 24, 2011.
34. Participation to the Spring Event, SINPE 2011, "Nutrition and oncology towards integration", Milan, March 25-26, 2011.
35. Participation as consultant to the meeting "Scientific HBV debrief" Monza, May 5, 2011.
36. Participation as consultant in the meeting TIDE entitled "HCV therapy today and future scenarios", Monza May 12, 2011.

37. Participation as invited speaker to the meeting "NATURAL HISTORY OF LIVER DISEASES: from hypertransaminasemia to liver transplantation," Mesagne (BR), June 11, 2011.
38. Participation as invited speaker to the meeting "Paths diagnostic and therapeutic in Rheumatology", Taranto, September 20-21, 2011.
39. Participation as invited speaker to the Training Course in General Medicine for a seminar on "Classification and treatment of viral hepatitis HBV and HCV" Bari, June 28-30, 2011.
40. Participation as invited speaker to CME course "Managing patients with chronic hepatitis B and C: New Perspectives", on the topic "Chronic hepatitis C: state of the art." Rome 28/10/2011.
41. Participation as invited speaker to CME course "Liver and Kidney", on the topic "HBV and renal failure." Bari 16/12/2011.
42. Participation to the International Expert Forum 6 "Hepatology perspectives - Indicators and predictors of treatment success" Madrid, January 13-14, 2012.
43. Participation as invited speaker to CME course "Parkinson's disease and neurodegenerative diseases," on the topic "enteral nutrition". Polignano a Mare, May 17-19, 2012.
44. Participation as invited speaker to CME course "99th National Congress SIO", on the topic "Nutritional therapy in post surgical cancer patients." Bari, May 23-26, 2012.
45. Participation as lecturer for the course "EMPATIE - Hepatitis B. Management of the disease: Encounters and Experiences ", Bari, 09/06/2012
46. Participation to the Congress "Update Meeting on HCV DAAs 2012: practical insights into patient management" Rome, September 25-26, 2012.
47. Participation as "discussant" to a residential event entitled "Viral hepatitis: general states of care" September 28-29, Foggia.
48. Participation to the conference "Beyond Nutrition Nutrients" 1st International Meeting on Lipids in Clinical Care " Venice, October 5, 2012.
49. Participation to the "Residential Course SINPE: the foundations of artificial nutrition in hospital and at home" Rocca di Papa, October 22-24, 2012.
50. Participation as lecturer for the course "VIRAL- dissemination of experiences in HBV", Bari, 24/10/2012.
51. Participation as invited speaker to CME course "Update in Gastroenterology: clinical and therapeutical aspects" on the topic "HBV infection and cryoglobulinemia". Taranto February 22-23, 2013.

52. Participation as invited speaker to CME course “Intestinal microbiota” on the topic “Microbiota manipulation as therapy for hepatic encephalopathy”. Bari 13/04/2013.
53. Participation as discussant to CME course “VIRAL – Real life experience in HBV patients” Bari, 07/06/2013.
54. Participation as invited speaker to CME course “Management of chronic Pancreatitis” on the topic “Clinical nutrition in course of chronic pancreatitis”. Bari 15/06/2013.
55. Participation as invited speaker to CME course “Todo sobre los medicamentos biológicos” held in Padula (SA), November 22-23, 2013.
56. Participation as invited speaker to XVI National Congress “Problems in Nutritional Therapy” on the topic “Assessment of fat mass in patients eligible for liver transplantation”. Ancona, November 28-30, 2013.
57. Participation as invited speaker to CME course “HCV infection therapy: experience with protease inhibitors” held in Foggia November 29-30, 2013.
58. Participation to 49th EASL International liver congress 2014, Lonon.
59. Participation as invited speaker to CME course “Meet the expert” held in Foggia May 22, 2014.
60. Participation as invited speaker to CME Congress “5th Biennial Congress on Actuality in Gastroenterology”, Manfredonia (FG), May 30-31, 2014.
61. Participation as invited speaker to CME course “Gastrointestinal damage in course of NSAID: how to prevent and when to prescribe”, Bari, July 05, 2014.
62. Participation to the Meeting - SINPE Spring Event 2015- “Advances in specialized artificial nutrition”, Roma, March 19-21, 2015
63. Participation as invited speaker to the SINPE course “The bases of artificial nutrition: hospital- and home-related aspects” Bari, April 15-17, 2015.
64. Participation as invited speaker to the CME Congress “Hepatocellular carcinoma: from biology to surgery” Castellana Grotte (BA) June 04-05, 2015.
65. Participation to the SINPE National Congress Naples, November 26-28, 2015.
66. Participation as Chair to the “Apulia 5th Tri-Society Congress” on the topic “Emergencies and Urgencies in Gastroenterology” Bari, April 1-2, 2016.
67. Participation as invited speaker to the CME Congress “Dysphagia and dysarthria in amyotrophic lateral sclerosis: diagnosis, treatment and rehabilitation” Bari 10/06/2016.
68. Participation as invited speaker to the International Workshop : "Nuclear Receptors and colorectal cancer". Bari 23/06/2016.

69. Participation as invited speaker to the CME Course of SINPE “The bases of artificial nutrition: hospital- and home-related aspects” Bari, October 27-29, 2016.
70. Participation as chair to the SINPE Monothematic Meeting on "Nutrition in Oncology" Trieste, Novembre 10-12, 2016.
71. Participation as speaker to the SINPE Monothematic Meeting on "Dietetics and clinical nutrition in the gastroenterological patient" Rome, Novembre 25-26, 2016.
72. Participation as speaker to the Meeting - SINPE Spring Event 2017- “Advances in specialized artificial nutrition” Salerno, March 16-17, 2017.
73. Participation to the Congress “FRANC’17: Critical Care Nutrition”, Munich, May 16-19, 2017.
74. Participation to the Congress “39th ESPEN Congress”, The Hague, September 9-12, 2017.
75. Participation to the Congress “Nutrients Beyond Nutrition 6”. Nutrients and Inflammation: from Genes to Bedside. Stresa, October 13, 2017.
76. Participation as speaker to the Meeting “Multidisciplinary management of the patient before and after transplantation” on the topic “Nutritional problems and liver transplantation”, Bari, October 27, 2017.
77. Participation as speaker to the course “1st Regional course dedicated to training, improvement, updating on neuromuscular diseases” on the topic “Eating disorders and nutrition in neuromuscular diseases” Bari, October 28, 2017.
78. Partecipazione al Congresso Nazionale SINPE dal titolo “La nutrizione clinica: un’opportunità per la medicina di oggi e di domani” Milano, 23-25 novembre 2017.
79. Partecipazione al 6° Congresso trisocietario pugliese dal titolo “Le reti in Gastroenterologia” in qualità di moderatore e di relatore sul tema “La rete nutrizionale in Puglia” Bari, 4-5 dicembre 2017.
80. Partecipazione allo Spring Event 2018 “Advances in specialized artificial nutrition”, in qualità di relatore sul tema “Il paziente affetto da SLA con PEG: valutazione del fabbisogno calorico. Perugia, 15-16 Marzo 2018.
81. Partecipazione al 24° Congresso Nazionale delle Malattie Digestive Roma, 21-24 marzo 2018.
82. Partecipazione al Corso ”Nutrizione clinica nel paziente oncologico” in qualità di relatore sul tema “Cachessia nel paziente oncologico” e “Integrazione ospedale-territorio nel paziente oncologico in nutrizione clinica” Foggia, 11-12 maggio 2018.
83. Partecipazione al Congresso dal titolo “Nuove frontiere nella eziopatogenesi, diagnosi e trattamento dell’encefalopatia epatica” in qualità di responsabile scientifico e di relatore sul

tema “Chi dovrebbe essere sottoposto a valutazione diagnostica e perché?” Bari, 26 maggio 2018.

84. Partecipazione al Congresso dal titolo “Nuove prospettive terapeutiche nella sindrome dell’intestino corto”. Bologna 21/09/2018.
85. Partecipazione al Congresso dal titolo “La gestione clinica del paziente anziano con sarcopenia”. Napoli 04/10/2018.
86. Partecipazione all’evento formativo “Mangi sano e stai sano. Scegliere l’alimentazione in modo consapevole” in qualità di relatore. Padula (SA) 03/11/2018.
87. Partecipazione al Congresso “La nutrizione parenterale nel paziente oncologico” in qualità di relatore con la presentazione dal titolo “Le nuove linee guida sul percorso nutrizionale del paziente oncologico”. Bari 15/01/2019
88. Partecipazione all’evento “Mela Talk on Tour” in qualità di relatore con la presentazione dal titolo “Dieta e nutrizione: sveliamo i falsi miti” Bari, 16 febbraio 2019.
89. Partecipazione al 25° Congresso Nazionale delle Malattie Digestive Roma, 27-30 marzo 2019.
90. Partecipazione al Corso “Linee guida e gestione dell’epatite C: Il paziente al centro del percorso diagnostico terapeutico ospedale-territorio” in qualità di relatore con la presentazione dal titolo “HCV & Rene” Venosa, 30 marzo 2019.
91. Partecipazione al V Workshop “I tumori del colon retto” Bari, 29-30 maggio 2019.
92. Partecipazione all’evento “Gastroudate” in qualità di relatore con la presentazione dal titolo “Vitamina D e malassorbimento” Bari, 7-8 giugno 2019.
93. Partecipazione dell’evento ECM patrocinato dalla SINPE “Dietetica e nutrizione clinica nel paziente gastroenterologico” in qualità di responsabile scientifico e di relatore sul tema “Influenza del supporto nutrizionale sull’outcome nelle neoplasie gastroenteriche”, Bari 24-25 giugno 2019.
94. Partecipazione all’evento “ESPEN LLL Course on Nutritional Assessment and Energy Expenditure”, Vienna 27-28 ottobre 2019.
95. Partecipazione in qualità di relatore al Corso “IG-IBD and SINPE practice course on diet and nutrition in inflammatory bowel disease”. Riccione 28 novembre 2019.
96. Partecipazione in qualità di relatore e responsabile scientifico al Corso ECM “PDTA per i pazienti a rischio di malnutrizione o malnutriti, che necessitano di nutrizione artificiale”. Bari, 29 novembre 2019.

97. Partecipazione VI Workshop “Update nel trattamento multidisciplinare del carcinoma gastrico” in qualità di relatore con la presentazione dal titolo “Screening nutrizionale nei pazienti con cancro gastrico e ruolo dell’immunonutrizione”. Bari 5-6 dicembre 2019.
98. Partecipazione al 37° Congresso Nazionale SIMG (Virtual Congress) in qualità di relatore con la presentazione dal titolo “La stipsi e la sindrome da defecazione ostruita”. 23 Novembre 2020 - 31 Marzo 2021.
99. Partecipazione VII Workshop “Update nel trattamento del carcinoma gastrico avanzato” in qualità di relatore con la presentazione dal titolo “La nutrizione nel paziente oncologico”. Bari 4 dicembre 2020.
100. Partecipazione al web meeting dal titolo “SINUC digital 2021 – update in nutrizione clinica” in qualità di relatore con la presentazione “Prebiotici e probiotici nelle MICI dal razionale all’evidenza clinica”. Dal 08-11 al 22-12-2021.
101. Partecipazione all’evento “PROGETTO YOUNG writing the future together”, in qualità di facilitator, Bari 08 ottobre 2021.
102. Partecipazione al corso ECM, dal titolo “Contributo della medicina integrata in oncologia”, in qualità di relatore con la presentazione dal titolo “Nutrizione clinica e immunonutrizione nel paziente oncologico” e di responsabile scientifico. Bari 5-6 novembre 2021.
Partecipazione al Congresso Nazionale SINPE, evento ECM, dal titolo “SINPE incontra”, Genova 25-27 novembre 2021.
103. Partecipazione al IX Workshop “Tumori maligni degli arti e del retroperitoneo. Sarcomi e neoplasie rare.” in qualità di relatore con la presentazione dal titolo “Malnutrizione e supporto nutrizionale perioperatorio nei pazienti con sarcoma retro peritoneale”. Bari 10/12/2021.
104. Partecipazione al “44th Congresso Nazionale Malattie Digestive”. Roma, 11-14 maggio, 2022.
105. Partecipazione al 3rd Edition of GLOBAL Congress on “Advances in Gastroenterology & Hepatology” in qualità di relatore con la presentazione dal titolo: Possible role of nuclear factor erythroid 2–related factor 2 in the development of human colon precancerous lesions. Parigi, 11-12 luglio, 2022.
106. Partecipazione al “28° ESPEN Congress. Vienna, 3-6 settembre, 2022.
107. Partecipazione al “8° Congresso Trisocietario AIGO-SIED-SIGE” in qualità di responsabile scientifico e di relatore con la presentazione dal titolo “Nutrizione clinica nei pazienti con tumori gastrointestinali”. Bari, 16-17 settembre, 2022.

108. Partecipazione alla “Riunione regionale pugliese dei centri di riferimento per la SLA: aspetti disfagici e nutrizionali” in qualità di relatore con la presentazione dal titolo “Aspetti nutrizionali nella SLA”. Bari 22/09/2021.
109. Partecipazione alla “5° Congresso Nazionale SINuC” in qualità di moderatore. Lecce, 27-29 settembre.
110. Partecipazione al corso ECM, dal titolo “Trattamento nutrizionale del paziente di medicina interna”, in qualità di relatore con la presentazione dal titolo “Screening, valutazione e tipologia di intervento nutrizionale alla luce delle Linee Guida ESPEN 2018”. Bari 28 ottobre 2022.

PUBLICATIONS : n. 1705

CONTRIBUTIONS TO BOOKS : n. 5

BOOKS

Francavilla A, TE Starzl, DH Van Thiel, **M Barone**, L Polimeno. Regeneration. In: Molecular and cell biology of the liver. A.V. LeBouton Ed; pp. 309-346, 1993.

Francavilla A, **M Barone**: Cancerogenesi e neoplasie del fegato. In: Malattie dell'apparato digerente. UNIGASTRO eds. ISBN 88-02-05772-9, UTET, pag. 283-290, 1998.

Francavilla A, **M Barone**: Cancerogenesi e neoplasie del fegato. In: Malattie dell'apparato digerente. UNIGASTRO eds. ISBN 88-02-05772-9, UTET, pag. 289-295, 2000.

Barone M, R Licinio, A Di Leo. Phytoestrogens as Nutritional Modulators in Colon Cancer Prevention. In: Cancer Prevention - From Mechanisms to Translational Benefits. Edited by A. Georgakilas. Publisher: InTech, 2012. pag 321-330. ISBN 978-953-51-0547-3

Facciorusso A, **Barone M**. Thermal Ablative Treatments for Hepatocellular Carcinoma. In: Hepatocellular Carcinoma. Third Edition. Carr BI (Ed). Springer International Publishing 2016. pp 453-466. ISBN: 978-3-319-34212-2

PUBLICATIONS

1. Francavilla A, L Polimeno, D Conte, **M Barone**, G Fanizza, A ChiuMarulo, G Rizzo, M Rubino. Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding non cancerous colonic tissue. *Gastroenterology* 1987;93:1301-1306.
2. Francavilla A, A Di Leo, PK Eagon, L Polimeno, F Guglielmi, G Fanizza, **M Barone**, TE Starzl. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver. *Gastroenterology* 1987;93:681-686.
3. Francavilla A, P Ove, L Polimeno, M Coetzee, L Makowka, **M Barone**, DH Van Thiel, TE Starzl. Regulation of liver size and regeneration: importance in liver transplantation. *Transplant Proc* 1988;20:494-97.
4. Francavilla A, P Ove, L Polimeno, M Coetzee, L Makowka, **M Barone**, DH Van Thiel, TE Starzl. Isolation and partial purification of hepatic stimulatory substance. *Transplant Proc* 1988;20: 719-21.
5. Francavilla A, L Makowka, L Polimeno, **M Barone**, J Demetris, FW Guglielmi, G Ambrosino, DH Van Thiel, TE Starzl. A novel model of acute hepatic failure in dogs with implications for transplantation research. *Transplant Proc* 1988;20:713-15.
6. Francavilla A, L Polimeno, A Di Leo, **M Barone**, P Ove, M Coetzee, P Eagon, L Makowka, G Ambrosino, V Mazzaferro, TE Starzl. The effect of estrogens and tamoxifen on hepatocyte proliferation in vivo and in vitro. *Hepatology* 1989;9:614-20.
7. Puca FM, F Antonaci, C Panella, FW Guglielmi, **M Barone**, A Francavilla, R Cerutti. Psychomotor disfunctions in alcoholic and post-necrotic cirrhotic patients without overt encephalopathy. *Acta Neurol Scand* 1989;79:280-287.
8. Francavilla A, J Gavalier, L Makowka, **M Barone**, V Mazzaferro, G Ambrosino, S Iwatsuki, FW Guglielmi, A Di Leo, Balestrazzi, DH Van Thiel TE Starzl. Estradiol and testosterone levels

in patients undergoing partial hepatectomy. A possible signal for hepatic regeneration?. Dig Dis Science 1989;34:818-822.

9. Francavilla A, L Polimeno, A Di Leo, L Makowka, **M Barone**, TE Starzl. Effect of cimetidine, ranitidine, famotidine and omeprazole on hepatocyte proliferation in vitro. J Hepatology 1989;8:32-41.
10. Francavilla A, **M Barone**, S Todo, Q Zeng, KA Porter, TE Starzl. Augmentation of rat liver regeneration by FK 506 compared with cyclosporine. Lancet, 1989;2:1248-1249.
11. Francavilla A, L Makowka, L Polimeno, **M Barone**, J Demetris, J Prelich, DH Van Thiel, TE Starzl. A dog model for acetaminophen-induced fulminant hepatic failure. Gastroenterology 1989;96:470-8.
12. Francavilla A, **M. Barone**, T.E. Starzl, A. Zeevi, C. Scotti, G. Carrieri, V. Mazzaferro, J. Prelich, S. Todo, G. Eiras, J. Fung, and K.A. Porter. FK 506 as a growth control factor. Transplant Proc 1990;23:90-92.
13. Panella C, L. Makowka, **M. Barone**, L. Polimeno, S. Rizzi, J. Demetris, S. Bell, F. W. Guglielmi, J. G. Prelich, D. H. Van Thiel, T. E. Starzl, and A. Francavilla. Effect of ranitidine on acetaminophen-induced hepatotoxicity in dogs. Dig Dis Sci 1990;35: 385-391.
14. Francavilla A, TE Starzl, **Barone M**, QH Zeng, KA Porter, A Zeevi, PM Markus, MRM Van Der Burck, S Todo. Studies on mechanism of augmentation of liver regeneration by cyclosporine and FK506. Hepatology 1991;14:140-143.
15. Francavilla A, TE Starzl, Ken Porter, C Scotti Foglieni, G Michalopoulos, G Carrieri, J Trejo, A Azzarone, **M Barone**, Qi Hua Zeng. Screening for candidate hepatic growth factors by selective portal infusion after canine Eck fistula. Hepatology 1991;14:665-670.
16. Polimeno L, A Azzarone, P Dell'aquila, C Amoruso, **M Barone**, A Angelini, DH Van Thiel, A Francavilla. Relationship between plasma and hepatic cytosolic levels of ornithine decarboxylase (ODC) and thymidine kinase (TK) in 70% hepatectomized rats. Dig Dis Sci 1991;36:289-292.
17. Francavilla A, **M Barone**, DH Van Thiel, V Mazzaferro, JG Prelich, TE Starzl. Further steps of hepatic stimulatory substance purification. Dig Dis Sci 1991;36:674-680.
18. Francavilla A, **M Barone**, A Azzarone, C Panella, A Giangaspero. Cell regeneration in the pathobiology of liver carcinomas. Ital J Gastroenterol 1991;23:589-593.
19. **Barone M**, C Panella, A Angelini, D Romanelli, A Francavilla. Studies in vitro on the influence of ursodeoxycholate sodium salt (UDC) on hepatocyte proliferation. J Surg Oncol 1993;3:8-13.
20. Francavilla A, L Polimeno, **M Barone**, A Azzarone, TE Starzl. Hepatic regeneration and growth factors. J Surg Oncol 1993;3:1-7.
21. **Barone M**, A Azzarone, A Angelini, M Zamparella, P Dell'aquila, A Francavilla. Effect of epomediol on taurocholate uptake in hepatocytes isolated from normal rats or rats with ethinylestradiol-induced cholestasis. Pharmacol Toxicol 1993;72:296-299.
22. Panella C, E Ierardi, M De Marco, **M Barone**, FW Guglielmi, L Polimeno, A Francavilla. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients affected by chronic liver disease ? Ital J Gastroenterol 1995;27: 256-8.

23. **Barone M**, A Francavilla L Polimeno, E Ierardi, D Romanelli, P Berloco, A Di Leo, C Panella. Modulation of rat hepatocyte proliferation by salts: in vitro and in vivo studies. *Hepatology* 1996;23:1159-1163.
24. Capuano F, **M Barone**, N D'eri, E Russo, D Varone, A Francavilla, S Papa. Ursodeoxycholate promotes protein phosphorylation in the cytosol of rat hepatocytes. *Biochem Mol Biol Int* 1997;41:329-337.
25. Cavallini A, C Messa, M Pricci, ML Caruso, **M Barone**, A Di Leo. Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. *Dig Dis Sci* 2002;47:2720-8.
26. **Barone M**, Berloco P, Ladisa R, Ierardi E, Caruso ML, Valentini AM, Notarnicola M, Di Leo A, Francavilla A. Demonstration of a direct stimulatory effect of bile salts on rat colonic epithelial cell proliferation. *Scand J Gastroenterol* 2002;37:88-94.
27. Ierardi E, A Di Leo, **M Barone**, S Marangi, O Burattini, A Panarese, M Margiotta, R Francavilla, C Panella, A Francavilla, R Cuomo. Tumor necrosis factor alpha and apoptosis in *Helicobacter pylori* related progressive gastric damage: a possible mechanism of immune system involvement in epithelial turnover regulation. *Immunopharmacol Immunotoxicol* 2003;25:203-11.
28. **Barone M**, Ettore GC, Ladisa R, Schiavariello M, Santoro C, Francioso G, Vinciguerra V, Francavilla A. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. *Hepatogastroenterology* 2003;50:183-7.
29. Ierardi E, N Muscatiello, M Nacchiero, M Gentile, M Margiotta, S Marangi, V De Francesco, R Francavilla, **M Barone**, D Faleo, C Panella, A Francavilla, R Cuomo. Second harmonic imaging improves trans-abdominal ultrasound detection of biliary sludge in "idiopathic" pancreatitis. *Aliment Pharmacol Ther* 2003;17:473-477.
30. Ierardi E, M Rendina, R Francavilla, **M Barone**, A Castellaneta, C Panella, A Francavilla, R Cuomo. Mycophenolate mofetil in the treatment of autoimmune HCV-associated haematological disorders showing steroid resistance or dependence. *J Viral Hepat* 2003;10:390-3.
31. **Barone M**, E Maiorano, R Ladisa, R Cuomo, A Pece, P Berloco, ML Caruso, AM Valentini, A Iolascon, A Francavilla, A Di Leo, E Ierardi. Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice. *Hepatology* 2003;37:880-886.
32. **Barone M**, Maiorano E, Ladisa R, Pece A, Berloco P, Strazzabosco M, Caruso ML, Valentini AM, Ierardi E, Di Leo A, Francavilla A. Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats. *Virchows Arch*. 2004;444:554-60.
33. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, Russo F, **Barone M**, Di Leo A, Minenna MF, Stoppino V, Morini S, Panella C, Francavilla A, Ierardi E. Sequential treatment for *Helicobacter pylori* does not share the risk factors of triple therapy failure. *Aliment Pharmacol Ther*. 2004;15:19:407-14.
34. **Barone M**. Hepatitis D-related cirrhosis and risk of hepatocellular carcinoma development. *Radiology* 2004;233:299.
35. Dell'Aquila P, Pietrini L, **Barone M**, Cela EM, Della Valle N, Amoruso A, Minenna MF, Penna A, De Francesco V, Panella C, Ierardi E. Small intestinal contrast ultrasonography-based

- scoring system A promising approach for the diagnosis and follow-up of celiac disease. *J Clin Gastroenterol* 2005;39:591-5.
36. Linsalata M, Russo F, Berloco P, Valentini Am, Caruso ML, De Simone C, **Barone M**, Polimeno L, Di Leo A. Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. *In Vivo* 2005;19:989-95.
 37. Di Marzio L, Di Leo A, Cinque B, Fanini D, Agnifili A, Berloco P, Linsalata M, Lorusso D, **Barone M**, De Simone C, Cifone MG. Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer. *Cancer Epidemiol Biomarkers Prev.* 2005;14:856-62.
 38. Avolio AW, **Barone M**. Use of "o" blood group liver donors for nonidentical recipients: does this represent a double penalty for "o" blood group candidates? *Transplant Proc* 2006;38:1063-5.
 39. **Barone M**, Di Lernia, Carbonara M, Ladisa R, Donno A, Amoruso A, Di Leo A, Francavilla A. Sliding gastric hiatal hernia diagnosis by transabdominal ultrasonography: an easy, reliable and non-invasive procedure. *Scand J Gastroenterol* 2006;41:851-5.
 40. **Barone M**, Spano D, D'apolito M, Centra M, Lasalandra C, Capasso M, Volinia S, Arcelli D, Di Leo A, Francavilla A, Tiribelli C, Iolascon A. Gene expression analysis in HBV transgenic mouse liver: a new insight into hepatocarcinogenesis. *Mol Med* 2006;12:115-23.
 41. Castellaneta A, Di Leo A, Francavilla R, Margiotta M, **Barone M**, Amoruso A, Troiani L. Thomson Aw, Francavilla A. Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice. *Hepatology* 2006;43:807-16.
 42. **Barone M**, Ladisa R, Di Leo A, Spano D, Francioso D, Aglio V, Amoruso A, Francavilla A, Iolascon A. Estrogen-induced proliferation in cultured hepatocytes involves cyclin d1, p21^{CIP1} and p27^{KIP1}. *Dig Dis Sci* 2006;51:580-6.
 43. Avolio AW, Agnes S, Gasbarrini A, Barbarino R, Nure E, Siciliano M, **Barone M**, Castagneto M. Allocation of nonstandard livers to transplant candidates with high MELD scores: Should this practice be continued? *Transplant Proc* 2006;38:3567-71.
 44. **Barone M**, Tanzi S, Lofano K, Scavo MP, Guido R, Demarinis L, Principi MB, Bucci A, Di Leo A. Estrogens, phytoestrogens and colorectal neoproliferative lesions. *Genes & Nutr* 2008;3:7-13.
 45. Di Leo A, **Barone M**, Maiorano E, Tanzi S, Piscitelli D, Marangi S, Lofano K, Ierardi E, Principi M, Francavilla A. ER-beta expression in large bowel adenomas: Implications in colon carcinogenesis. *Dig Liver Dis* 2008;40:260-6.
 46. **Barone M**, Avolio AW, Di Leo A, Burra P, Francavilla A. ABO blood group related waiting list disparities in liver transplant candidates: effect of the MELD adoption. *Transplantation* 2008;85:844-849.
 47. **Barone M**, Margiotta M, Scavo MP, Gentile A, Francioso D, Papagni S, Castellaneta A, Mallamaci R, Di Leo A, Francavilla A. Possible involvement of androgen receptor alterations in hepatocarcinogenesis. *Dig Liver Dis* 2009;41:665-70.
 48. **Barone M**, Maiorano E, Scavo MP, Panella E, Castellaneta A, Napoli A, Francioso D, Di Leo A, and Francavilla A. Effect of gonadectomy on HCC development in HBV transgenic mice. *Dig Liver Dis* 2009;41:150-155.

49. Nardone G, Compare D, Liguori E, Di Mauro V, Rocco A, **Barone M**, Napoli A, Lapi D, Iovene MR, Colantuoni A. Protective effects of lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. *Am J Physiol Gastrointest Liver Physiol*. 2010; 299:G669-676.
50. **Barone M**, Scavo MP, Papagni S, Piscitelli D, Guido R, Di Lena M, Comelli MC, Di Leo A. ER β expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis. *Scand J Gastroenterol*. 2010; 45:1320-1308.
51. **Barone M**, Tanzi S, Lofano K, Scavo MP, Pricci M, Demarinis L, Papagni S, Maiorano E, Ingravallo G, Guido R, Comelli MC, Francavilla A, Di Leo A. Dietary-induced er β up-regulation counteracts intestinal neoplasia development in intact male Apc^{MIN/+} mice. *Carcinogenesis* 2010;31:269-74.
52. Avolio AW, Agnes S, Siciliano M, Grieco A, Nicolotti N, Annicchiarico E, Boscarino, G, **Barone M**. Donor Risk Index and MELD score interactions in graft survival prediction after liver transplantation. An analysis of the OPTN-UNOS database. *Open Transplantation Journal*, Volume 5, Issue SPEC. ISSUE, 2011, Pages 50-55.
53. Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S; Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. *Am J Transplant*. 2011 Dec;11(12):2724-36. **Collaborators (71) Barone M**
54. **Barone M**, Iannone A, Corvace V, Tanzi S, Montenegro L, Licinio R, Di Leo A. Anti-Viral Therapy in Chronic HBV Infection: A Single Centre Experience. *Hepatogastroenterology*. 2011 Sep-Oct;58(110-111):1713-7.
55. Avolio AW, Siciliano M, **Barone M**, Lai Q, Caracciolo GL, Barbarino R, Nicolotti N, Lirosi MC, Gasbarrini A, Agnes S. Model for end-stage liver disease dynamic stratification of survival benefit. *Transplant Proc*. 2012 Sep;44(7):1851-6.
56. Principi M, De Tullio N, Scavo MP, Piscitelli D, Marzullo A, Russo S, Albano F, Lofano K, Papagni S, **Barone M**, Ierardi E, Di Leo A. Estrogen receptors expression in long-lasting ulcerative pancolitis with and without dysplasia: A preliminary report. *Scand J Gastroenterol* 2012 Oct;47(10):1253-4.
57. **Barone M**, Lofano K, De Tullio N, Licino R, Albano F, Di Leo A. Dietary, Endocrine, and Metabolic Factors in the Development of Colorectal Cancer. *J Gastrointest Cancer*. 2012 Mar;43(1):13-9.
58. Principi M, Di Leo A, Pricci M, Scavo MP, Guido R, Tanzi S, Piscitelli D, Pisani A, Ierardi E, Comelli MC, **Barone M**. Phytoestrogens/insoluble fibers and colonic estrogen receptor β : randomized, double-blind, placebo-controlled study. *World J Gastroenterol*. 2013 Jul 21;19(27):4325-33.
59. **Barone M**, Licinio R, Amoruso A, Viggiani MT, Larocca AM, Di Leo A. Lesson from an intriguing case of cryoglobulinemia. *World J Gastroenterol*. 2013 Jan 14;19(2):304-6.
60. **Barone A**, A Di Leo. Estrogen receptor beta in colorectal cancer prevention: do we have conclusive proof? *J Genet Syndr Gene Ther* 2013, 4:11.

61. **Barone M**, Altomare DF, Rotelli MT, Scavo MP, Piscitelli D, De Tullio N, Bocale D, Di Leo A. Disseminated tumour cells in bone marrow in experimental colon cancer: metastatic or resident? *Colorectal Dis* 2013;15(6):667-73.
62. Ierardi E, Giorgio F, Piscitelli D, Principi M, Cantatore S, Fiore MG, Rossi R, **Barone M**, Di Leo A, Panella C. Altered molecular pattern of mucosal healing in Crohn's disease fibrotic stenosis. *World J Gastrointest Pathophysiol*. 2013 Aug 15;4(3):53-8.
63. Palmieri O, Ippolito AM, Margaglione M, Valvano MR, Gioffreda D, Fasano M, D'Andrea G, Corritore G, Milella M, Andriulli N, Morisco F, Giannitrapani L, Latiano A, Fontana R, Gatti P, Tundo P, **Barone M**, Cozzolongo R, Santantonio T, Andriulli A. A. Variation in genes encoding for interferon λ -3 and λ -4 in the prediction of HCV-1 treatment-induced viral clearance. *Liver international* October 2014; 34(9):1369-77. doi:10.1111/liv.12411
64. Principi M, **Barone M**, Pricci M, De Tullio N, Losurdo G, Ierardi E, Di Leo A. Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role? *World J Gastroenterol* 2014;20:11496-504.
65. Francavilla A, Pesetti B, **Barone M**, Morgano A, Bovenga F, Napoli A, Resta L, Russo F, Linsalata M, Minoia M, Bianco G, Tafaro A, Polimeno L. Transient GFER knockdown in vivo impairs liver regeneration after partial hepatectomy. *Int J Biochem Cell Biol*. 2014 May 28; 53C:343-351. doi: 10.1016/j.biocel.2014.05.029
66. Facciorusso A, Del Prete V, Antonino M, Neve V, Crucinio N, Di Leo A, Carr BI, **Barone M**. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. *J Gastroenterol Hepatol*. 2014; 29:1905-10. doi: 10.1111/jgh.12618
67. Facciorusso A, Amoruso A, Neve V, Antonino M, Prete VD, **Barone M**. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. *World J Hepatol*. 2014; 6:793-9. doi: 10.4254/wjh.v6.i11.793.
68. Facciorusso A, Del Prete V, Antonino M, Crucinio N, Neve V, Di Leo A, Carr BI, **Barone M**. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. *Digestive and Liver Disease* 2014; 46:1014-9. doi: 10.1016/j.dld.2014.07.012.
69. **Barone M**, Notarnicola M, Caruso MG, Scavo MP, Viggiani MT, Tutino V, Polimeno L, Pesetti B, Di Leo A, Francavilla A. Olive oil and omega-3 polyunsaturated fatty acids suppress intestinal polyp growth by modulating the apoptotic process in ApcMin/+ mice. *Carcinogenesis* 2014;35:1613-9. doi: 10.1093/carcin/bgu068
70. **Barone M**, Viggiani MT, Amoruso A, Licinio R, Iannone A, Montenegro L, Scavo MP, Addante I, Di Leo A. Influence of age and type of underlying disease on complications related to home enteral nutrition: a single Italian center experience. *JPEN J Parenter Enteral Nutr* 2014 Nov;38(8):991-5.
71. Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, Calvaruso V, Gioffreda D, Milella M, Morisco F, Felder M, Brancaccio G, Fasano M, Gatti P, Tundo P, **Barone M**, Cozzolongo R, Angelico M, D'Andrea G, Andriulli N, Abate ML, Mazzella G, Gaeta GB, Craxi A, Santantonio T. Identification of naïve HCV-1 patients with

- chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. *J Hepatol*. 2014 Jan;60(1):16-21. doi: 10.1016/j.jhep.2013.07.040.
72. **Barone M**, Iannone A, Di Leo A. HBsAg clearance by Peg-Interferon addition to a long-term nucleos(t)ide analogues therapy. *World J Gastroenterol* 2014; 20: 8722-5. doi: 10.3748/wjg.v20.i26.8722
 73. Facciorusso A, **Barone M**. Glucose intolerance and hepatocellular carcinoma: recent findings for old diseases. *Hepatobiliary Surg Nutr*. 2014;3:91-2. doi: 10.3978/j.issn.2304-3881.2014.02.15.
 74. **Barone M**, Scavo MP, Maiorano E, Di Leo A, Francavilla A. Bone marrow-derived stem cells and hepatocarcinogenesis in hepatitis B virus transgenic mice. *Dig Liver Dis*. 2014 Mar; 46(3):243-50. doi: 10.1016/j.dld.2013.10.008.
 75. Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrilu C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators (**Barone M**). An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. *Dig Liver Dis*. 2014 Sep;46(9):818-25. doi: 10.1016/j.dld.2014.05.015
 76. Facciorusso A, Antonino M, Del Prete V, Neve V, Scavo MP, **Barone M**. Are hematopoietic stem cells involved in hepatocarcinogenesis? *Hepatobiliary Surg Nutr*. 2014;3:199-206. doi: 10.3978/j.issn.2304-3881.2014.06.02.
 77. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, **Barone M**. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. *World J Hepatol* 2015;7:2009-19. doi: 10.4254/wjh.v7.i16.2009
 78. Giorgio F, Principi M, Losurdo G, Piscitelli D, Iannone A, **Barone M**, Amoruso A, Ierardi E, Di Leo A. Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg? *Nutrients* 2015;7:7486-504. doi: 10.3390/nu7095350.
 79. **Barone M**, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, Iannone F, Avolio AW, Di Leo A, Cantarini L, Lapadula G. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. *Hepatology*. 2015;62:40-46. doi: 10.1002/hep.27716.
 80. **Barone M**, Scavo MP, Licinio R, Piombino M, De Tullio N, Mallamaci R, Di Leo A. Role of Bone Marrow-Derived Stem Cells in Polyps Development in Mice with Apc(Min/+) Mutation. *Stem Cells Int*. 2015;2015:354193. doi: 10.1155/2015/354193.
 81. Facciorusso A, Di Maso M, Antonino M, Del Prete V, Panella C, **Barone M**, Muscatiello N. Polidocanol injection decreases the bleeding rate after colon polypectomy: a propensity score analysis. *Gastrointest Endosc* 2015;82:350-358. doi: 10.1016/j.gie.2015.01.003
 82. Facciorusso A, Antonino M, Di Maso M, **Barone M**, Muscatiello N. Non-polypoid colorectal neoplasms: Classification, therapy and follow-up. *World J Gastroenterol* 2015; 21:5149-5157. doi: 10.3748/wjg.v21.i17.5149.

83. **Barone M.** Neurophysiologic and psychometric tests in the diagnosis of low-grade encephalopathy. *Gastroenterology*. 2015 Mar;148(3):663. doi: 10.1053/j.gastro.2014.10.062
84. Facciorusso A, Licinio R, Carr BI, Di Leo A, **Barone M.** MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. *Expert Rev Gastroenterol Hepatol* 2015; 9:993-1003. doi: 10.1586/17474124.2015.1040763.
85. Facciorusso A, Antonino M, Del Prete V, Amoruso A, Neve V, **Barone M.** Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile. *Curr Drug Saf* 2015; 10: 202-207.
86. **Barone M,** Iannone A, Brunetti ND, Sebastiani F, Cecere O, Berardi E, Antonica G, Di Leo A. Liver stiffness and portal blood flow modifications induced by a liquid meal consumption: pathogenetic mechanisms and clinical relevance. *Scand J Gastroenterol* 2015;50:560-6. doi: 10.3109/00365521.2014.1003396
87. Facciorusso A, Muscatiello N, **Barone M.** Letter: prognostic scoring systems for hepatocellular carcinoma patients--the jury is still out. *Aliment Pharmacol Ther* 2015;41:596-7. doi: 10.1111/apt.13078
88. **Barone M,** Viggiani MT, Amoruso A, Schiraldi S, Zito A, Devito F, Cortese F, Gesualdo M, Brunetti N, Di Leo A, Scicchitano P, Ciccone MM. Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. *Gastroenterol Res Pract.* 2015; 2015:682174. doi: 10.1155/2015/682174
89. Facciorusso A, Del Prete V, Antonino M, Neve V, Amoruso A, Crucinio N, Di Leo A, **Barone M.** Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation *Hepatol Res* 2015;45:E62-72. doi: 10.1111/hepr.12458.
90. Facciorusso A, Muscatiello N, Di Leo A, **Barone M.** Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: a glimmer of light after the storm trial? *Am J Gastroenterol* 2015;110:770-1. doi: 10.1038/ajg.2015.80.
91. Facciorusso A, Del Prete V, Crucinio N, Muscatiello N, Carr BI, Di Leo A, **Barone M.** Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. *J Gastroenterol Hepatol* 2015; 30:1643-50. doi: 10.1111/jgh.12988.
92. Scavo MP, Gentile E, Wolfram J, Gu J, **Barone M,** Evangelopoulos M, Martinez JO, Liu X, Celia C, Tasciotti E, Vilar E, Shen H. Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. *Colloids Surf B Biointerfaces* 2015;136:694-703. doi: 10.1016/j.colsurfb.2015.10.005
93. Facciorusso A, Maso MD, **Barone M,** Muscatiello N. Echoendoscopic ethanol ablation of tumor combined to celiac plexus neurolysis improved pain control in a patient with pancreatic adenocarcinoma. *Endosc Ultrasound* 2015;4:342-44.

94. Facciorusso A, Del Prete V, Muscatiello N, Crucinio N, **Barone M**. Prognostic role of 25-hydroxyvitamin d in patients with liver metastases from colorectal cancer treated with radiofrequency ablation. *J Gastroenterol Hepatol* 2016 Feb 20. doi: 10.1111/jgh.13326.
95. **Barone M**, Della Valle N, Rosania R, Facciorusso A, Trotta A, Cantatore FP, Falco S, Pignatiello S, Viggiani MT, Amoruso A, De Filippis R, Di Leo A, Francavilla R. A comparison of the nutritional status between adult celiac patients on a long-term, strictly gluten-free diet and healthy subjects. *Eur J Clin Nutr* 2016;70:23-7. doi: 10.1038/ejcn.2015.114.
96. Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, Morosi C, Cascella T, Marchianò A, Camerini T, Bhoori S, Brunero F, **Barone M**, Mazzaferro V. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. *J Gastroenterol Hepatol* 2016;31:645-53. doi: 10.1111/jgh.13147
97. Losurdo G, Iannone A, Principi M, **Barone M**, Ranaldo N, Ierardi E, Di Leo A. Acute pancreatitis in elderly patients: A retrospective evaluation at hospital admission. *Eur J Intern Med* 2016;30:88-93. doi: 10.1016/j.ejim.2016.01.011. Epub 2016 Jan 22.
98. Principi M, Cassano N, Contaldo A, Iannone A, Losurdo G, **Barone M**, Mastrolonardo M, Vena GA, Ierardi E, Di Leo A. Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. *World J Gastroenterol*. 2016 May 28;22(20):4802-11. doi: 10.3748/wjg.v22.i20.4802
99. Iannone A, Losurdo G, Pricci M, Girardi B, Massaro A, Principi M, **Barone M**, Ierardi E, Di Leo A. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis. *J Gastrointest Cancer* 2016;47:143-51. doi: 10.1007/s12029-016-9810-z.
100. Losurdo, G., Iannone, A., Giorgio, F., **Barone, M.**, Principi, M., Ierardi, Di Leo, A. Sequential therapy for helicobacter pylori in elderly patients: Effectiveness, safety and predictors of success. *Letters in Drug Design and Discovery* 2017;14:1-6.
101. Losurdo G, Principi M, Girardi B, Pricci M, **Barone M**, Ierardi E, Di Leo A. Histamine and histaminergic receptors in colorectal cancer: from basic science to evidence-based medicine. *Anticancer Agents Med Chem*. 2016 Mar 21. [Epub ahead of print]
102. Notarnicola M, **Barone M**, Francavilla A, Tutino V, Bianco G, Tafaro A, Minoia M, Polimeno L, Napoli A, Scavo MP, Caruso MG. Lovastatin, but not orlistat, reduces intestinal polyp volume in an ApcMin/+ mouse model. *Oncol Rep* 2016;36:893-9. doi: 10.3892/or.2016.4856.
103. Iannone A, Principi M, **Barone M**, Losurdo G, Ierardi E, Di Leo A. Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients? *Clin Res Hepatol Gastroenterol* 2016;40:373-377.
104. Losurdo G, Giorgio F, Piscitelli D, Montenegro L, Covelli C, Fiore MG, Giangaspero A, Iannone A, Principi M, Amoruso A, **Barone M**, Di Leo A, Ierardi E. May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? *World J Gastroenterol*. 2016 Sep 21;22(35):8017-25. doi: 10.3748/wjg.v22.i35.8017.

105. Giorgio F, Ierardi E, Sorrentino C, Principi M, **Barone M**, Losurdo G, Iannone A, Giangaspero A, Monno R, Di Leo A. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. *Scand J Gastroenterol*. 2016 Dec;51(12):1429-1432.
106. Losurdo G, Giorgio F, Iannone A, Principi M, **Barone M**, Di Leo A, Ierardi E. Role of concomitant therapy for Helicobacter pylori eradication: A technical note. *World J Gastroenterol*. 2016 Oct 14;22(38):8638-8640
107. Licinio R, Losurdo G, Carparelli S, Iannone A, Giorgio F, **Barone M**, Principi M, Ierardi E, Di Leo A. Helicobacter pylori, liver cirrhosis, and portal hypertension: an updated appraisal. *Immunopharmacol Immunotoxicol*. 2016 Oct 27:1-6.
108. Giannitti C, Lopalco G, Vitale A, Rigante D, Anelli MG, Fabbroni M, Manganelli S, Galeazzi M, Frediani B, **Barone M**, Lapadula G, Iannone F, Cantarini L. Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. *Clin Exp Rheumatol* 2017;35:93-97.
109. **Barone M**, Shahini, E., Di Leo, A. Letter: can transient elastography and body mass index predict fibrosis regression in HBV patients on long-term nucleoside therapy? *Alimentary Pharmacology and Therapeutics* 2017; 45:765-766.
110. Losurdo G, Marra A, Shahini E, Girardi B, Giorgio F, Amoruso A, Pisani A, Piscitelli D, **Barone M**, Principi M, Di Leo A, Ierardi E. Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis. *Neurogastroenterology and Motility* 2017; 29:e13028.
111. Lopalco G, Rigante D, Venerito V, Fabiani C, Franceschini R, **Barone M**, Lapadula G, Galeazzi M, Frediani B, Iannone F, Cantarini L. Update on the Medical Management of Gastrointestinal Behçet's Disease. *Mediators Inflamm* 2017;2017:1460491.
112. Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, **Barone M**, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: is it time for tailored first-line therapy? *World Journal of Gastroenterology* 2017; 23:2453-2458.
113. Ippolito AM, Milella M, Messina V, Conti F, Cozzolongo R, Morisco F, Brancaccio G, **Barone M**, Santantonio T, Masetti C, Tundo P, Smedile A, Carretta V, Gatti P, Termite AP, Valvano MR, Bruno G, Fabrizio C, Andreone P, Zappimulso M, Gaeta GB, Napoli N, Fontanella L, Lauletta G, Cuccorese G, Metrangolo A, Francavilla R, Ciraci E, Rizzo S, Andriulli A. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. *Dig Liver Dis* 2017;49:1022-1028.
114. **Barone M**, Viggiani MT, Losurdo G, Principi M, Leandro G, Di Leo A. Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. *Aliment Pharmacol Ther*. 2017;46:236-245. doi: 10.1111/apt.14139

115. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; **ABACUS study group**; AIFA team. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. *Lancet Gastroenterol Hepatol.* 2017;2:427-434
116. Ierardi E, Losurdo G, Iannone A, Piscitelli D, Amoruso A, **Barone M**, Principi M, Pisani A, Di Leo A. Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored? *Ann Gastroenterol.* 2017;30:380-392.
117. **Barone M**, Viggiani MT, Losurdo G, Principi M, Leandro G, Di Leo A. Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity—authors' reply. *Aliment Pharmacol Ther* 2017;46:460-461.
118. **Barone M**, Iannone A, Shahini E, Ippolito AM, Brancaccio G, Morisco F, Milella M, Messina V, Smedile A, Conti F, Gatti P, Santantonio T, Tundo P, Lauletta G, Napoli N, Masetti C, Termite AP, Francavilla R, Di Leo A, Pesce F, Andriulli A. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study. *J Viral Hepat* 2017;1-7.
119. **Barone M**, Viggiani MT, Avolio AW, Iannone A, Rendina M, Di Leo A. Obesity as predictor of postoperative outcomes in liver transplant candidates: Review of the literature and future perspectives. *Digestive and Liver Disease* 2017; 49:957–966. doi: 10.1016/j.dld.2017.07.004.
120. Viggiani MT, Lorusso O, Natalizio F, Principi M, Di Leo A, **Barone M**. Influence of chemotherapy on total energy expenditure in patients with gastrointestinal cancer: A pilot study. *Nutrition* 2017;42:7-11. doi: 10.1016/j.nut.2017.05.001
121. Ranaldo N, Losurdo G, Iannone A, Principi M, **Barone M**, De Carne M, Ierardi E, Di Leo A. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease. *Cell Death Dis.* 2017;8:e3040.
122. Ippolito AM, Iacobellis A, Milella M, Conti F, Messina V, Valvano MR, Niro GA, Morisco F, **Barone M**, Termite AP, Brancaccio G, Andriulli A. Hepatitis C Virus Clearance in Older Adults. *J Am Geriatr Soc* 66:85–91, 2018.
123. Iannone A, Ruospo M, Wong G, Principi M, **Barone M**, Strippoli GFM, Di Leo A. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials. *Clinical Gastroenterology and Hepatology* 2017;15:1684–1697.
124. **Barone M**, Viggiani MT, Losurdo G, Principi M, Leandro G, Di Leo A. Letter: dose-response

- analysis revealed closer relationship between obesity and perioperative outcomes in patients after liver transplantation. *Aliment Pharmacol Ther.* 2018 Jan;47(2):312-313. doi: 10.1111/apt.14446.
125. Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A. Probiotic monotherapy and *Helicobacter pylori* eradication: A systematic review with pooled-data analysis. *World J Gastroenterol.* 2018; 24:139-149. doi: 10.3748/wjg.v24.i1.139.
126. Losurdo G, Principi M, Iannone A, Amoruso A, Ierardi E, Di Leo A, Barone M. Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm. *World J Gastroenterol.* 2018; 24:1521–1530. doi: 10.3748/wjg.v24.i14.1521
127. Barone M, Shahini E, Iannone A, Viggiani MT, Corvace V, Principi M, Di Leo A. Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis. *Dig Liv Dis.* 2018;50:496-500. 10.1016/j.dld.2018.01.133
128. Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. *Infection.* 2018 May 28. doi: 10.1007/s15010-018-1157-x.
129. Principi M, Losurdo G, Iannone A, Contaldo A, Deflorio V, Ranaldo N, Pisani A, Ierardi E, Di Leo A, Barone M. Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population. *Ann Gastroenterol.* 2018; 31: 469–473. doi: 10.20524/aog.2018.0273.
130. Girardi B, Principi M, Pricci M, Giorgio F, Iannone A, Losurdo G, Ierardi E, Di Leo A, Barone M. Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model. *Carcinogenesis* 2018; 39:1274-1282.
131. Barone M. Is the use of the BMI alone sufficient to diagnose malnutrition in both male and female adults? *Clin Nutr.* 2018;37:1771. doi: 10.1016/j.clnu.2018.07.003
132. Losurdo G, Principi M, Iannone A, Giangaspero A, Piscitelli D, Ierardi E, Di Leo A, Barone M. Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study. *Nutrients.* 2018 18;10. pii: E2001. doi: 10.3390/nu10122001.
133. Shahini E, Iannone A, Romagno D, Armandi A, Carparelli S, Principi M, Viggiani MT, Ierardi

- E, Di Leo A, Barone M. Clinical relevance of serum non-organ-specific 1 antibodies in HCV patients receiving direct-acting antiviral therapy. *Aliment Pharmacol Ther* 2018; 48:1138-1145.
134. Iannone A, Ruospo M, Wong G, Barone M, Principi M, Di Leo A, Strippoli GFM. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials. *Can J Gastroenterol Hepatol*. 2018;2018:5437135.
135. Principi M, Iannone A, Losurdo G, Mangia M, Shahini E1, Albano F, Rizzi SF, La Fortezza RF, Lovero R, Contaldo A, Barone M, Leandro G, Ierardi E, Di Leo A. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. *Inflamm Bowel Dis*. 2018;24:1589-1596.
136. Barone M, Viggiani MT, Anelli MG, Fanizzi R, Lorusso O, Lopalco G, Cantarini L, Di Leo A, Lapadula G, Iannone F. Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. *J Clin Med*. 2018;7(12).
137. Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients with Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. *J Clin Gastroenterol* 2019; 53:117-e125. DOI: 10.1097/MCG.0000000000001023 Scopus ID: 2-s2.0-85057948260
138. Contaldo A, Losurdo G, Albano F, Iannone A, Barone M, Ierardi E, Di Leo A, Principi M. The Spectrum of Small Intestinal Lesions in Patients with Unexplained Iron Deficiency Anemia Detected by Video Capsule Endoscopy. *Medicina (Kaunas)* 2019;55:59. doi: 10.3390/medicina55030059
139. Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. J. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. *J Hepatol* 2019; 71:473-485. DOI: 10.1016/j.jhep.2019.04.017. SCOPUS ID: 2-s2.0-85067690668.
140. Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. *World J Gastroenterol*. 2019 May 28;25(20):2524-2538. doi: 10.3748/wjg.v25.i20.2524.
141. Viggiani MT, Di Leo A, Barone M. Can the antisecretory factor be considered a new therapy

for the short bowel syndrome? *Nutr Metab Insights*. 2019 May 23;12:1178638819852061. doi: 10.1177/1178638819852061

142. Rendina M, Viggiani MT, Di Leo A, Barone M. Malnutrition, sarcopenia, and refractory ascites in end stage liver diseases: is there a way to climb back up? *Dig Liver Dis*. 2019 Jul 2. pii: S1590-8658(19)30639-5. doi: 10.1016/j.dld.2019.06.002.
143. Viggiani MT, Polimeno L, Di Leo A, Barone M. Phytoestrogens: Dietary Intake, Bioavailability, and Protective Mechanisms against Colorectal Neoproliferative Lesions. *Nutrients*. 2019;11(8). pii: E1709. doi: 10.3390/nu11081709.
144. Ierardi E, Losurdo G, Fortezza RF, Principi M, Barone M, Di Leo A. Optimizing proton pump inhibitors in *Helicobacter pylori* treatment: Old and new tricks to improve effectiveness. *World J Gastroenterol* 2019;25:5097-5104. doi: 10.3748/wjg.v25.i34.5097
145. Iannone A, Ruospo M, Palmer SC, Principi M, Barone M, Di Leo A, Strippoli GFM. Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease. *Aliment Pharmacol Ther* 2019;50:858-871. Doi: 10.1111/apt.15493. SCOPUS ID: 2-s2.0-85072019090
146. Barone M, Viggiani MT, Intronà A, D'errico E, Scarafino A, Iannone A, Di Leo A, Simone IL. Nutritional prognostic factors for survival in amyotrophic lateral sclerosis patients undergone percutaneous endoscopic gastrostomy placement. *Amyotroph Lateral Scler Frontotemporal Degener*. 2019 Jul 26:1-7. doi: 10.1080/21678421.2019.1643374
147. Polimeno L, Barone M, Mosca A, Viggiani MT, Di Leo A, Debellis L, Troisi M, Daniele A, Santacroce L. Gut Microbiota Imbalance is Related to Sporadic Colorectal Neoplasms. A Pilot Study. *Appl. Sci*. 2019, 9, 5491; doi:10.3390/app9245491.
148. Daniele A, Paradiso AV, Divella R, Digennaro M, Patruno M, Tommasi S, Pilato B, Tufaro A, Barone M, Minoia C, Colangelo D, Savino E, Casamassima P, Bruno E, Oliverio A, Pisanisi P. The Role of Circulating Adiponectin and SNP276G>T at ADIPOQ Gene in BRCA-mutant Women. *Cancer Genomics Proteomics* 2020;17(3):301-307. doi: 10.21873/cgp.20190.
149. Losurdo G, Leandro G, Ierardi E, Perri F, Barone M, Principi M, Di Leo A. Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. *J Neurogastroenterol Motil* 2020;26:16-28. doi: 10.5056/jnm19113.
150. Piazzolla M, Castellana N, Novelli A, Agolini E, Cocciadiferro D, Resta L, Duda L, Barone M, Ierardi E, Di Leo A. Nonsense variant of ATP8B1 gene in heterozygosis and benign

recurrent intrahepatic cholestasis: A case report and review of literature. *World J Hepatol* 2020; 12 (2), 64-71. Doi: 10.4254/wjh.v12.i2.0000

151. Cerletti C, Colucci M, Storto M, Semeraro F, Ammollo CT, Incampo F, Costanzo S, De Bartolomeo G, Portincasa P, Barone M, Di Castelnuovo A, Semeraro N, Iacoviello L, De Gaetano G. Randomized trial of chronic supplementation with a nutraceutical mixture to subjects with Non Alcoholic Fatty Liver Disease (NAFLD). *British J Nutr.* 2020;123:190-197. doi: 10.1017/S0007114519002484
152. Barone M, Gemello E, Viggiani MT, Cristofori F, Renna C, Iannone A, Di Leo A, Francavilla R. Evaluation of non-celiac gluten sensitivity in patients with previous diagnosis of irritable bowel syndrome: a randomized double-blind placebo-controlled crossover trial. *Nutrients* 2020, 12, 705; doi:10.3390/nu12030705.
153. Polimeno L, Barone M, Mosca A, Viggiani MT, Joukar F, Mansour-Ghanaei F, Mavaddati S, Daniele A, Debellis L, Bilancia L, Santacroce L, Di Leo A. Soy Metabolism by Gut Microbiota from Patients with Precancerous Intestinal Lesions. *Microorganisms* 2020, 8, 469; doi:10.3390/microorganisms8040469
154. Francavilla R, Cristofori F, Vacca M, Barone M, Maria De Angelis. Advances in understanding the potential therapeutic applications of gut microbiota and probiotic mediated therapies in celiac disease. *Expert Review of Gastroenterology & Hepatology*, DOI: 10.1080/17474124.2020.1745630
155. Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, Marzi L, Pellegatta G, Borgia G, Gambato M, Terreni N, Serio I, Belli L, Oliveri F, Maimone S, Brunacci M, D'Ambrosio R, Forzenigo LV, Russo FP, Rumi M, Barone M, Fracanzani AL, Raimondo G, Giannini EG, Brunetto MR, Villa E, Biganzoli E, Colombo M, Lampertico P. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. *J Hepatol* 2020;73:593-602. doi: 10.1016/j.jhep.2020.03.030.
156. Girardi B, Pricci M, Giorgio F, Piazzolla M, Iannone A, Losurdo G, Principi M, Barone M, Ierardi E, Di Leo A. Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model. *World J Gastroenterol* 2020 April 14; 26(14): 0-0. DOI: 10.3748/wjg.v26.i14.0000.
157. Barone M, Di Leo A, Sabbà C, Mazzocca A. The perplexity of targeting genetic alterations in hepatocellular carcinoma. *Med Oncol.* 2020;37:67. doi: 0.1007/s12032-020-01392-8.
158. Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Chronic viral

hepatitis in a cohort of inflammatory bowel disease patients from southern Italy: A case-control study. *Pathogens* 2020;9:1-10. doi: 10.3390/pathogens9110870

159. Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Trends of liver stiffness in inflammatory bowel disease with chronic hepatitis C. *Diagnostics (Basel)*. 2020 Dec 2;10(12):1037. doi: 10.3390/diagnostics10121037.
160. Losurdo G, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. *World J Gastroenterol*. 2020 Dec 21;26(47):7528-7537. doi: 10.3748/wjg.v26.i47.7528.
161. Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body. *Front Immunol*. 2021 Feb 26;12:578386. doi: 10.3389/fimmu.2021.578386.
162. Delvecchio M, Bizzoco F, Lapolla R, Gentile A, Carrozza C, Barone M, Simonetti S, Giordano P, Dargenio VN, Cristofori F, Francavilla R. Iodine Absorption in Celiac Children: A Longitudinal Pilot Study. *Nutrients*. 2021 Mar 1;13(3):808. doi: 10.3390/nu13030808.
163. Barone M, Suppressa P, Viggiani MT, Lenato GM, Scardapane A, Chiumarulo L, Ambrosini N, Leo AD, Sabbà C. Minimal portosystemic encephalopathy: A new nosological entity in patients with hereditary haemorrhagic telangiectasia. *Eur J Intern Med* 2021 May 18;S0953-6205(21)00149-7. doi: 10.1016/j.ejim.2021.04.026.
164. Cristofori F, D'Abramo FS, Rutigliano V, Dargenio VN, Castellaneta S, Piscitelli D, De Benedittis D, Indrio F, Raguseo LC, Barone M, Francavilla R. Esophageal eosinophilia and eosinophilic esophagitis in celiac children: A ten-year prospective observational study. *Nutrients* 2021 24;13(11):3755. doi: 10.3390/nu13113755.
165. Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? *World J Hepatol*. 2021 Nov 27;13(11):1534-1551. doi: 10.4254/wjh.v13.i11.1534.
166. Barone M, Venerito V, Paolillo R, Emmi G, Fornaro M, Cacciapaglia F, Cantarini L, Di Leo A, Iannone F, Lopalco G. Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. *Intern Emerg Med*. 2022 Mar;17(2):475-480. doi: 10.1007/s11739-021-02836-3
167. Polimeno L, Viggiani MT, Giorgio F, Polimeno L, Fratantonio D, Di Domenico M, Boccellino M, Ballini A, Topi S, Di Leo A, Santacroce L, Barone M. Possible role of nuclear factor

erythroid 2-related factor 2 in the progression of human colon precancerous lesions. *Dig Liver Dis.* 2022 Feb 21;S1590-8658(22)00142-6. doi: 10.1016/j.dld.2022.01.131.

168. Colaianni G, Oranger A, Dicarlo M, Lovero R, Storlino G, Pignataro P, Fontana A, Di Serio F, Ingravallo A, Caputo G, Di Leo A, Barone M, Grano M. Irisin Serum Levels and Skeletal Muscle Assessment in a Cohort of Charcot-Marie-Tooth Patients. *Front Endocrinol (Lausanne).* 2022 May 12;13:886243. doi: 10.3389/fendo.2022.886243.
169. Concas G, Barone M, Francavilla R, Cristofori F, Dargenio VN, Giorgio R, Dargenio C, Fanos V, Marcialis MA. Twelve Months with COVID-19: What Gastroenterologists Need to Know. *Dig Dis Sci.* 2022 Jul;67(7):2771-2791. doi: 10.1007/s10620-021-07158-0.
170. Barone M, Losurdo G, Iannone A, Leandro G, Di Leo A, Trerotoli P. Assessment of body composition: Intrinsic methodological limitations and statistical pitfalls. *Nutrition.* 2022 May 14;102:111736. doi: 10.1016/j.nut.2022.111736.
171. Rendina M, Paoletti E, Labarile N, Marra A, Iannone A, Castellaneta A, Bussalino E, Ravera M, Schena A, Castellaneta NM, Barone M, Simone S, Gesualdo L, Di Leo A. HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels. *Ther Adv Chronic Dis.* 2022 Sep 17;13:20406223221117975

Prof. Michele Barone